Servier said it would buy Day One Biopharmaceuticals, the maker of a drug for childhood brain tumors, in a deal worth roughly $2.5 billion.
LONDON — The French pharma company Servier said Friday that it would buy Day One Biopharmaceuticals, the maker of a drug for childhood brain tumors, in a deal worth roughly $2.5 billion.
Servier, which is privately held, is paying $21.50 a share in cash for Day One, a roughly 68% premium on the Bay Area biotech’s closing price on Thursday.
The deal’s centerpiece
is Day One’s Ojemda
, which
won U.S. approval in 2024
as a treatment for pediatric low-grade glioma, the most common form of childhood brain cancer. Servier said the deal would expand its pipeline of experimental medicines for rare cancers.
Continue to STAT+ to read the full story…
— Source: STAT News (https://www.statnews.com/2026/03/06/servier-dayone-pediatric-cancer/)
